About
Technology
Issues
FAQ
Links
Official Page
A randomized phase 2b trial of baricitinib, an oral Janus kinase (
JAK
) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.